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Abstract
Background: Infectious diseases after solid organ transplantation (SOT) are one of the major complications in
transplantation medicine. Vaccination-based prevention is desirable, but data on the response to active vaccination after
SOT are conflicting.
Methods: In this systematic review, we identify the serologic response rate of SOT recipients to post-transplantation
vaccination against tetanus, diphtheria, polio, hepatitis A and B, influenza, Streptococcus pneumoniae, Haemophilus
influenzae, Neisseria meningitides, tick-borne encephalitis, rabies, varicella, mumps, measles, and rubella.
Results: Of the 2478 papers initially identified, 72 were included in the final review. The most important findings are that (1)
most clinical trials conducted and published over more than 30 years have all been small and highly heterogeneous
regarding trial design, patient cohorts selected, patient inclusion criteria, dosing and vaccination schemes, follow up periods
and outcomes assessed, (2) the individual vaccines investigated have been studied predominately only in one group of SOT
recipients, i.e. tetanus, diphtheria and polio in RTX recipients, hepatitis A exclusively in adult LTX recipients and mumps,
measles and rubella in paediatric LTX recipients, (3) SOT recipients mount an immune response which is for most vaccines
lower than in healthy controls. The degree to which this response is impaired varies with the type of vaccine, age and organ
transplanted and (4) for some vaccines antibodies decline rapidly.
Conclusion: Vaccine-based prevention of infectious diseases is far from satisfactory in SOT recipients. Despite the large
number of vaccination studies preformed over the past decades, knowledge on vaccination response is still limited. Even
though the protection, which can be achieved in SOT recipients through vaccination, appears encouraging on the basis of
available data, current vaccination guidelines and recommendations for post-SOT recipients remain poorly supported by
evidence. There is an urgent need to conduct appropriately powered vaccination trials in well-defined SOT recipient
cohorts.
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Introduction
The numbers of solid organ transplant (SOT) recipients have
substantially increased in recent decades. Transplant rejection
rates decreased with improved immunosuppression and quality of
life increased with better post-transplant care. Donor- and
recipient- derived, opportunistic, nosocomial or community
acquired infections including newly emerging infectious diseases
and malignancies remain a problem, however [1,2]. Most
infections in SOT recipients are associated with high morbidity
and mortality compared to immunocompetent individuals. Fur-
thermore, more powerful immunosuppressive drugs, such as
biologic agents are changing the pattern of infection with new,
previously unknown infection risks [3,4].
Vaccination is the most efficient and cost effective intervention
to prevent infectious diseases in healthy persons [5]. The response
to vaccines with subsequent protection against infectious diseases,
however, is depending on a functioning immune system.
Despite current recommendations emphasizing the importance
of vaccinating SOT candidates prior to transplantation, reality
tells a different story: vaccine coverage studies have demonstrated
that this goal is far from being achieved. In the pre-transplantation
phase practical problems of timely vaccination are difficult to
overcome and concerns by both patients and doctors about
vaccine-induced side effects are the main reason for the reluctant
vaccination uptake in the post-transplantation period [6,7].
Guidelines and recommendations for vaccination of SOT
recipients are poorly supported by evidence and are largely
extrapolated from what is known for healthy persons. For new
immunosuppressive regimens and recently approved vaccines,
recommendations are solely based on theoretical considerations.
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We systematically review published data on the vaccination
response of SOT recipients to summarize current knowledge and
to identify areas where research is needed.
Methods
Search Strategy
We systematically reviewed published work in accordance with
the PRISMA guidelines [8]. We performed an electronic search
with the following medical subject heading (MESH) terms:
‘‘immunization’’, ‘‘vaccination’’ and ‘‘organ transplantation’’ in
PubMed, Embase and Cochrane Central Register of Controlled
Trials without time restriction till end of December 2011. The
search was restricted to articles on human research and English
language. References of the papers identified and of relevant
reviews and books were additionally searched.
Trial Selection
We included original research papers published in peer-
reviewed scientific journals reporting results on adult or paediatric
SOT recipients that were vaccinated with currently licensed
vaccines (see Table 1). We included all studies in which
vaccination appeared warranted as defined by those who designed
and conducted the study. This definition included studies where
SOT recipients were considered unvaccinated in the pre-
transplant era, SOT recipients whose vaccination status was not
updated before transplantation, SOT recipients with negative
antibody status or with unknown vaccination status.
Serologic immune response to vaccination had to be assessed at
least once after vaccination. All types of vaccines that are currently
in use independent of the vaccination schedule, combination and
dosing were accepted. No restriction regarding study design was
applied.
We excluded studies on vaccination of transplant candidates or
organ donors, experimental vaccines or adjuvants, comparative
trials on routes of application, trials on vaccines that are out of use
and trials on pandemic vaccines. We excluded articles where
humoral (serologic) response) was not assessed, key data were
missing or not extractable (number of SOT recipients vaccinated,
rate of response, and time of vaccination), when no primary data
were given (all reviews, editorials, guidelines, letter to the editor
and comments), case and conference reports. Further, we excluded
trials on vaccination for prevention of hepatitis B recurrence due
to HBV-related liver disease, transplant recipients with a history of
HBV infection or anti-HBc positive grafts. If the same group of
Table 1. Criteria and definitions for study selection and data analysis.
A
Inclusion criteria Active vaccination
Licensed vaccine still in use
Adult or paediatric SOT recipients on immunosuppressive medication
Exclusion criteria Vaccination of solid organ transplant candidates or donors
Experimental vaccines
Experimental adjuvants
Comparative trials on routes of vaccine application
Vaccines out of use
Pandemic vaccines
Humoral (serologic) response not assessed
Key data missing (number of vaccines, rate of response, and time of vaccination)
No primary data given (reviews, editorials, guidelines, letter to the editor and comments on other articles)
Case reports
Conference reports
Trials on prevention of HBV recurrence in liver graft recipients with a history of HBV infection or anti-HBc positive grafts.
B
Term Definition
SOT recipients Recipient of an organ graft receiving immunosuppression
Routine vaccination Vaccines which are licensed and currently in use
Indication for vaccination Vaccination appeared warranted as defined by those who designed and conducted the trials (SOT recipients considered unvaccinated in
the pre-transplant era, vaccination status was not updated before transplantation, negative antibody status or unknown vaccination
status)
Positive response Humoral (serological) vaccine response as rate of seroconversion, if available, or as serological response defined as ‘‘protective’’ by the
authors
Short-term response* Positive response .2 weeks and #3 months post-vaccination
Long-term response* Positive response $12 months post-vaccination
Inclusion and exclusion criteria (A) and definitions used for study selection and data analysis (B).
*If a shorter time interval was accepted exceptionally, this is indicated in the text or by a footnote.
doi:10.1371/journal.pone.0056974.t001
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SOT recipients was described in more than one article, only the
report with the more detailed data presentation was included.
All articles obtained in the search were reviewed on the basis of
the title in a first step, if the title was unclear, the abstract was
additionally reviewed (exclusion step one). After subtraction of
duplicates, articles were checked for inclusion criteria on the basis
of the abstract or the full text (exclusion step two). Articles not
fulfilling the inclusion criteria were excluded (exclusion step three).
Hard copies of the articles fulfilling all inclusion criteria were
obtained and the data extracted with a data extraction sheet.
Additionally, the reference list of relevant articles and reviews were
searched (for data flow, see Figure 1). Both authors performed all
selection steps independently.
Data Extraction
From all articles remaining after exclusion step two the
following data were extracted: Type of trial, type of SOT, age-
group of SOT recipients (adult/paediatric), type of vaccine,
vaccination schedule (number of doses and timing), number of
SOT recipients and controls vaccinated, proportion of subjects
(SOT recipients and, if given, controls) with vaccine response, time
of follow up (defined time interval between vaccination and
serological tests), cut-offs used for definition of vaccine response
and immunosuppressive regimen.
Data Analysis
As outcome of interest we choose the serologic response to
vaccination and report the overall proportion of SOT recipients
with vaccine response at two time points after vaccination. For our
analysis the vaccination response defined by the authors of the
individual studies was accepted as valid. Short-term response was
defined as the humoral (serological) vaccine response measured as
rate of seroconversion where this information is available, or as
serological response defined as ‘‘protective’’ by the authors two
weeks to three months after vaccination. Long-term response was
defined as humoral (serological) vaccine response measured after
12 months or longer. If a shorter time interval was exceptionally
accepted as long-term response, this is indicated (Table 1).
For detailed analysis, we grouped all articles obtained in the
following categories: category A includes all studies on vaccination
against tetanus, diphtheria, and polio. Category B includes
vaccination against viral hepatitis A and B (HAV and HBV).
Category C includes vaccination against seasonal influenza;
category D includes vaccination against bacterial pathogens
(Streptococcus pneumonia, Haemophilus influenzae, and Neisseria meningit-
ides). Category E includes all live virus vaccines (mumps, measles,
rubella and varicella) and category F includes vaccination against
pathogens indicated in certain geographical areas (tick-borne
encephalitis virus and rabies virus) (Table 2).
Forest Plot
We calculated the percentage of seropositive individuals at
follow-up by dividing the number of patients with positive
response by the total number of patients with exact binomial
95% confidence intervals (CIs) separately for each vaccination
group in each study and displayed these in forest plots. Studies
which only reported calculated percentage numbers were not
included. For influenza forest plots, only studies which assessed
response to every one of the three single antigens (H1N1, H3N2
and B) were included in the forest plot. We used meta-regression to
compare response proportions, for example between adult and
paediatric transplant recipients. The standard error for the
response proportion in a study was derived from the lower and
upper confidence limit of the response proportion. Serological
responses in transplant patients were compared with those of
comparison groups when available in each study with the use of
the risk difference (RDs) and 95% CIs either assuming a common-
effect by using the Mantel-Haenszel method or by using the
DerSimonian and Laird random-effects meta-analysis as imple-
mented in the ‘‘metan’’ command in Stata [9]. We quantified
between-trial heterogeneity with use of the I-squared statistic [10].
Results
In total, we obtained 2478 articles in the search (Figure 1).
Based on title, 303 potentially suitable articles of those were
selected. Remained articles which were checked for duplicates,
then for inclusion/exclusion criteria on the basis of abstract, or, if
not all the necessary information was provided in the abstract, on
the basis of the full text. From these articles, in total 233 articles
were excluded.
64 articles obtained through the initial search fulfilled all
inclusion criteria. By searching the reference lists of relevant
articles, reviews and books, 8 papers were additionally identified.
In total 72 papers were included into the review.
Of the trials that fulfilled the inclusion criteria (Table 3),
publication date ranged from 1980 to 2011. There were
prospective controlled (n = 32), prospective uncontrolled (n = 30),
retrospective (n = 4), and randomized (n= 5) trials and, although
initially defined as exclusion criteria but due to its relevance, one
case report (n = 1) included in the review. Some trials used more
than one trial design within the same publication on different
Table 2. Categories of vaccinations used and rationale for grouping.
Category Vaccinations against Rationale for grouping
A Tetanus, Diphtheria, Polio Inactivated vaccines which are frequently given as combined vaccination, part of regular childhood
immunization scheme
B Hepatitis A, Hepatitis B Inactivated vaccines against viral hepatitis, available as combination vaccine
C Influenza The only vaccine which is indicated yearly and has a seasonally changing antigen composition, inactivated
trivalent vaccine includes three different antigens (H1N1, H3N2 and B)
D Streptococcus pneumoniae, Haemophilus
influenzae, Neisseria meningitides
Inactivated vaccines against bacterial pathogens
Streptococcus pneumoniae: available either as polysaccharide or conjugate vaccine, response includes a large
number of antigens (7 or 23 serotypes) which differ in their immunogenicity
E Varicella, Mumps, Measles, Rubella Attenuated live virus vaccines which are given in childhood, available as combination vaccine
F Tick-borne encephalitis, Rabies Vaccines which are indicated for certain geographical areas, not part of the basic vaccination scheme
doi:10.1371/journal.pone.0056974.t002
Vaccination after Solid Organ Transplantation
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patient cohorts. Of the five randomized trials, three randomized to
the type of vaccine used (two for pneumococcal conjugate vaccine
vs. polysaccharide vaccine [11,12] and one for influenza vaccine
subunit vs. virosomal vaccine [13]), one trial on influenza
vaccination was randomized for the immunosuppressive regimen
(calcineurin-inhibitor vs. sirolimus [14]) and one trial which
primarily observed graft rejection was randomized to intervention
(single dose influenza vaccination vs. no vaccination [15]). In total,
65 trials were investigating inactivated vaccines in both adults and
children and seven trials investigated live attenuated vaccines
solely in paediatric SOT recipients. Inclusion of a control group
was highly variable with control groups entirely missing for HBV
and for live vaccines. At the opposite end the majority of influenza
vaccine trials had control groups.
Numbers of SOT recipients vaccinated ranged from 1 to 165
and healthy control numbers ranged from 7 to 109. There were 47
trials on vaccination of adult SOT and 25 of paediatric SOT
recipients. Most trials included renal transplant recipients (RTX,
31 articles), followed by liver transplant (LTX, 18 articles), heart
transplant (HTX, 11 articles), lung transplant (PTX, 2 articles) or
mixed cohorts of organ transplant recipients (9 articles). Of the
vaccines studied, inactivated influenza vaccination was the most
common (36 articles), followed by vaccination against Streptococcus
pneumoniae (9 articles), hepatitis B (7 articles), tetanus (6 articles),
varicella (6 articles), diphtheria (4 articles), mumps, measles,
rubella (4 articles), hepatitis A (3 articles), vaccination against
Haemophilus influenzae (2 articles), rabies vaccine (2 article), polio (1
article), Neisseria meningitides (1 article) and tick-borne encephalitis
vaccine (1 article). Some studies investigated more than one
vaccine in the same cohort. No studies were found on Bordetella
pertussis, rotavirus, human papilloma virus vaccines or vaccines
recommended for certain geographic areas ("travel vaccines" such
as yellow fever, typhoid fever or Japanese encephalitis vaccines)
apart from tick-borne encephalitis vaccine and rabies.
Most trials only assessed the short-term response within two
weeks to three months after vaccination. Only a few also measured
long-term responses at a second time point. Data on long-term
response were not always extractable for all SOT recipients with a
positive response at first assessment after vaccination. Most trials,
despite small patient numbers, addressed vaccine safety issues.
None of the trials neither on inactivated or on live vaccines,
however, reported severe adverse events (SAEs) or transplant-
related complication such as organ rejection after vaccination
during the time period of the trial.
Short-term Response
Category A: Vaccination against tetanus, diphtheria, polio.
Tetanus. We retrieved six trials investigating the response to
tetanus toxoid vaccination in SOT recipients with publication
dates ranging from 1995 to 2010 (Table 3, category A) [16–21].
Four trials were prospective uncontrolled and two prospective
controlled. All trials assessed the short-term response; two trials
additionally assessed the long-term response [17,20]. Three trials
included adult SOT recipients and three trials paediatric SOT
recipients. All trials were performed only on RTX recipients.
Patient numbers ranged from 7 to 150 in SOT recipients and 13 to
96 in the control group.
In five of six studies high response rates ranging from of 85%–
100% were seen [16–20] with no significant difference in the
response rates of SOT recipients and healthy controls in controlled
trials [16,18]. Response rates were lower in the study by Puissant-
Lubrano et al., which compared conventional immunosuppression
to immunosuppression with an anti-CD20 monoclonal antibody
(61.5% vs. 30.6%, respectively) (Table 3, category A) [21].
Overall, vaccination with tetanus toxoid in the post-transplant
period elicits a high rate of responders in SOT recipients with
conventional immunosuppression with no significant difference to
healthy controls (p = 0.96 on only two studies) while immunosup-
pression with anti-CD20 monoclonal antibody showed a decreased
response rate compared to conventional immunosuppressive
medication (p = 0.043 in meta-regression) (Table 3 and Figure 2,
category A).
Diphtheria. Four trials were identified with SOT recipients
vaccinated against diphtheria with publication dates ranging from
Figure 1. Flowchart of study selection.
doi:10.1371/journal.pone.0056974.g001
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1997 to 1999 (Table 3, category A) [17–20]. Three trials were
prospective uncontrolled while one trial was prospective con-
trolled. Three trials were performed on paediatric SOT recipients,
one trial assessed adult SOT recipients, and all were RTX
recipients. Patient numbers ranged from 33 to 164 SOT
recipients; the controlled trial had 106 controls.
Short-term response rates ranged from 88.5% to 95% with
comparable response rates in SOT recipients and controls (88.5%
vs. 96.2%, respectively) [17,18]. All studies with diphtheria
vaccination in the post-transplant phase show comparable high
response rates (I-squared = 0%).
Polio. Only one trial with an inactivated polio vaccine (IPV)
in SOT recipients was identified published in 1997 (Table 2,
category A) [18]. Short-term response rate in this prospective
controlled cohort of adult RTX recipients was 91.6% compared to
97.9% in controls, which shows high response for polio vaccine in
the post-transplant era with no significant difference to controls
(p = 0.125 based on own calculations) (see Table 3, group A).
Category B: Vaccination against viral hepatitis A and B.
Hepatitis A. Three trials on hepatitis A (HAV) vaccination in
SOT recipients were included with publication dates ranging from
1999 to 2001, two were prospective uncontrolled and one
prospective controlled (Table 3, category B) [22–24]. All trials
were in adult recipients of either liver or kidney grafts. The trials
addressed primary immunization schemes with two successive
vaccine doses. Patient numbers ranged from 8 to 39 SOT
recipients, the controlled trial had 27 controls. Maximal response
rates after two vaccinations ranged from 0% [22], which in
contrast applied a vaccination scheme with month 0 and 2
compared to all other trial with month 0 and 6, to 26% in one
study [24] and 97.4% in LTX recipients and 71.8% in RTX
recipients compared to 100% response in controls [23]. Overall,
results for HAV vaccination show a high degree of heterogeneity
(I-squared = 97.7%). While one study shows high response rates
for both RTX and LTX, others did not confirm this finding
(Figure 2, category B).
Hepatitis B. We identified seven trials on hepatitis B
vaccination after SOT with publication dates ranging from 1992
to 2001 (Table 3, category B) [25–31]. Six trials were prospective
uncontrolled while one trial was retrospective. None of the trials
had a control group. Five trials were performed in LTX recipients
with three in a paediatric and two in an adult LTX cohort, one
Figure 2. Forest plot for short-term response for vaccines from category A (tetanus, diphtheria, polio), B (hepatitis A and B), D
(Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitides), E (varicella, mumps, measles, rubella) and F (tick-borne
encephalitis and rabies). All article types are included. Numbers in brackets refer to legend in Table 3.
doi:10.1371/journal.pone.0056974.g002
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trial was conducted on adult heart- and one on adult kidney
transplant recipients, respectively. Patient numbers ranged from 4
to 86 SOT recipients. Most trials applied a multi dose scheme. In
adult SOT recipients, the response rate was low ranging from
6.7% to 36% while in contrast, a high response rate was seen in
the paediatric trials ranging from 63.6% to 100% (Figure 2,
category B) [29–31]. Overall, response rate to HBV after
transplantation in adult SOT recipients is poor while in paediatric
SOT recipients a 58% (95 CI: 37%–80%) higher response rate
was seen (p= 0.001 from meta-regression).
Category C: Vaccination against seasonal influenza.
In total, 36 trials on inactivated trivalent influenza vaccination
after SOT were included in the review with publication dates
ranging from 1980 to 2011 and vaccines against the circulating
strains of the influenza season of 1981/82 to 2007/2008 [13–
15,32–64].
In nine trials a prospective uncontrolled trial design was used
while 25 were prospective controlled, one trial was retrospective.
Three RCT were identified which were randomized to the
number of vaccine doses applied [15], to the type of immunosup-
pressive medication [14] and the vaccine type used [13]. Some
trials applied more than one study design within one publication.
Six trials investigated response in paediatric SOT recipients. 30
trials were conducted in adult SOT recipients. Patient numbers
ranged from 5 to 165 for SOT recipients and from 5 to 109 for
controls. Most trials were on RTX recipients (n = 19), followed by
LTX (n= 11), HTX (n= 9) and PTX (n=3) recipients.
Vaccination response was in most trials investigated as the
response to each of the three components A/H1N1, A/H3N2 and
B (Figure 3, 4, 5), while others only observed overall response to
influenza A or B or only total overall response (the latter two type
of trials are not displayed in a figure). The most common applied
vaccination scheme was single dose while some trials investigated a
double or even triple dose scheme of the same vaccine, however in
several controlled trials the control group received a different
vaccination scheme than SOT recipients (single vs. multi dose
regimen, respectively). Conflicting results were found for multiple
versus single dose vaccination in SOT recipients. While some trials
revealed an increased response rate after multiple dose vaccination
in SOT recipients, in other trials this was less clear. Furthermore,
the multiple dose regimen was not applied in most control groups.
None of the trials assessed long-term vaccination responses.
In the trials comparing different immunosuppressive drugs,
calcineurin-inhibitors and azathioprin were associated with a
slightly better response compared to sirolimus and mycophenolate
mofetil (Figure 3, 4, 5) [14,56].
Overall, variability of the response was very high and ranged
from 0–100% in SOT recipients with corresponding high values of
I-squared (all larger than 92%) (Figure 3, 4, 5). When comparing
response rate of SOT recipients with controls, several studies
Figure 3. Forest plot for short-term response for vaccine category C (influenza) against influenza H1N1. All type of trials which assessed
specific response to H1N1 are included. Numbers in brackets refer to legend in Table 3.
doi:10.1371/journal.pone.0056974.g003
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showed a clear trend to a less pronounced response in SOT
recipients with overall a 10% to 16% lower response rate in SOT
recipients (Figure 6, 7, 8). The difference in response to control
patients was in renal and lung transplant recipients less
pronounced than in the other SOT groups. In some studies,
however, the response rate in SOT recipients was even higher
than in controls. Almost all trials, however, observed a measurable
vaccine response at least in a subset of SOT recipients after single
dose vaccination with a trend to lower response rates in SOT
recipients compared to healthy controls in most of the trials.
Category D: Vaccination against bacterial pathogens.
Streptococcus pneumonia. Nine studies were identified
which investigated pneumococcal vaccine in SOT recipients with
publication dates ranging from 1998 to 2011 (Table 3, category D)
[11,12,42,65–70].
The trial design was prospective uncontrolled in five trials, and
prospective controlled in two trials. Two RCTs were randomized
to the type of vaccine given. Three trials were on paediatric and
five on adult SOT recipients. There were trials on SOT recipients
of kidney (3 trials), heart (3 trials), and three trials on mixed
cohorts.
In four trials responses to a randomized or mixed vaccination
scheme with both types of vaccines were investigated. Overall
response ranged from 32% to 100% with comparable responses in
the control group, if included [42,68]. Response rate was assessed
either as response to at least one serotype from a group of
representative antigens or an overall or mean response to selected
antigens. Those antigens selected as ‘‘representative’’ varied
between trials. Response rate in all studies was above 50% with
a summary estimate of 83% (95% CI: 83%–93%) with substantial
heterogeneity (I-squared= 81%) (Figure 2, category D).
Haemophilus influenzae (Hib). We retrieved two prospec-
tive trials on Hib vaccination in SOT recipients published in 1998
and 1999, one prospective controlled in RTX and one prospective
uncontrolled in HTX recipients (Table 3, category D) [66,71].
The vaccination responses were 56% in adult RTX recipients
compared to 71% in controls [71] and 85% in paediatric HTX
recipients [66] one month after vaccination with Hib conjugate
vaccine. Long-term responses were not assessed. An acceptable
response rate above 50% in SOT recipients in both studies was
observed (Figure 2, category D).
Neisseria meningitides. We retrieved one study which
investigated vaccination with conjugated meningitis C vaccine in
a mixed cohort of paediatric SOT recipients [72]. A positive short-
term response after 3 months was seen in all patients (Figure 2,
category D), however the authors stated that titers waned rapidly.
Category E: Vaccination with attenuated live virus vaccines.
Varicella. Six trials on live-attenuated varicella vaccination
after SOT were identified with publication dates ranging from
1994 to 2008 (Table 3, category E) [73–78]. Five were prospective
Figure 4. Forest plot for short-term response for vaccine category C (influenza) against influenza H3N2. All type of trials which assessed
specific response to H3N2 are included. Numbers in brackets refer to legend in Table 3.
doi:10.1371/journal.pone.0056974.g004
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uncontrolled and one was retrospective. All trials were conducted
in paediatric SOT recipients with three trials on RTX recipients,
[73,74,76] two trials on LTX [77] and one trial on a mixed cohort
of recipients of liver or intestine grafts [75]. Short-term response
rates ranged from 64.5% to 87%. Acceptable response rates were
observed in all studies with an overall estimate of 73% (95% CI:
64%–83%) with little heterogeneity (I-squared= 0%) in SOT
recipients after post-transplantation vaccination are seen (Figure 2,
category E).
Mumps, measles and rubella. Four trials on mumps,
measles and rubella vaccination in SOT recipients were identified
with publication dates ranging from 1993 to 2008 [74,77–79].
Two trials were retrospective and one prospective uncontrolled,
none of the trials assessed long-term responses. Only two trials
specified the immune response to the individual components of the
vaccine. Overall, all trials had small patient numbers ranging from
6 to 26 SOT recipients with a vaccination response ranging from
39% to 100%. In the two larger retrospective studies by Khan
et al. and Rand et al., which observed response rates over a time
period of 15 months and 5 years, respectively, lower response rates
were observed. In the trial by Shinjoh et al., high response rates in
a very small patient number was seen with a lower response rate to
the mumps component of the vaccine (Table 2, category E).
Overall, the observed positive response rates were above 70% in
all but one study conducted in 1993 resulting in a summary
estimate of 85% (95% CI: 72%–99%) with substantial heteroge-
neity (I-squared= 76%) (Figure 2, category E). Omitting the 1993
study reduced heterogeneity substantially (I-squared= 36%).
Category F: Vaccines indicated in certain geographical areas.
Tick-borne encephalitis. One trial was included that
measured vaccination response after TBE vaccination, published
in 1999 (Table 3, category F) [80]. In this prospective controlled
trial, TBE vaccination in an endemic area in Germany was studied
in 31 HTX recipients. SOT recipients responded in 35.5%,
controls in 100% (Figure 2, category F).
Rabies. Two trials were found that assessed immune response
to rabies vaccine in SOT recipients which were exceptionally
included despite not meeting all inclusion criteria [81,82] and
despite the fact that in both trials active and passive vaccination
was performed, due to the global relevance of rabies and the
importance to know the response of SOT recipients to standard
post-exposure vaccination as the only remedy after a potential risk
contact (Table 3, category F). Vaccination response to the post-
exposure vaccination scheme was analysed in an uncontrolled
retrospective trial in 8 paediatric SOT recipients [82] and in an
adult kidney transplant patient [81]. In the study by Cramer et al.,
the short-term response was 87.5% and in a 6 months assessment,
anti-rabies antibodies were found in 100% of SOT recipients.
Because of the relevance of this finding, we exceptionally included
the 6-month response into our analysis. In contrast, the case report
Figure 5. Forest plot for short-term response for vaccine category C (influenza) against influenza B. All type of trials which assessed
specific response to B are included. Numbers in brackets refer to legend in Table 3.
doi:10.1371/journal.pone.0056974.g005
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by Rodriguez-Romo et al. reported a decrease of antibodies
already 28 days after vaccination after adequate levels were
initially reached after the third dose of vaccine. Reduction of
immunosuppression and booster doses recovered adequate anti-
body levels (Figure 2, category F). In both trials passive
immunization may have led to an overestimation of the vaccine
response. The summary response rate estimate seen in these 9
SOT recipients was 89% (95% CI: 52%–100%) (Figure 2,
category F).
Long-term Response of SOT Recipients
Only few studies assessed a long-term response after $12
months, these were Enke et al. and Pedrazzi et al. for the tetanus
trials, Huzly et al. and Pedrazzi et al. for the diphtheria, Gu¨nther
et al. for hepatitis A vaccination and rabies with the caveats of
passive immunization and a time period of 6 months instead of 12,
Cramer et al. (Figure 9) [17,18,20,23,82]. Long-term response for
tetanus showed persistence of antibodies without relevant decrease
while diphtheria and polio long-time responses were decreasing
(polio not included in the figure because absolute number of SOT
recipients in the long-term cohort not assessable). A strong decline
in antibodies after vaccination was also seen for hepatitis A vaccine
with a decline 97.4% to 59.3% and 71.8% to 26.1%. Overall,
based on this limited number of studies that assessed both short-
and long-term response to vaccinations, the response for
diphtheria had a 17% (95% CI: 7%–27%) and the one for
hepatitis A 41% (95% CI: 26%–57%) decline over time in SOT
recipients (Figure 9).
Discussion
To the best of our knowledge, this is the first systematic review
of the literature on vaccination response of currently licensed
vaccines in SOT recipients.
The most important finding is that most clinical trials conducted
and published over more than 30 years have all been small and
highly heterogeneous regarding trial design, patient cohorts
selected, patient inclusion criteria, dosing and vaccination
schemes, follow up periods and outcomes assessed. The evidence
base for vaccination recommendations for SOT recipients thus
remains poor.
Our review had two main strengths: The systematic strategy
and broad search terms used to identify studies in a wide range of
databases and the rigorous methods used to extract and appraise
the data. The main limitation of this review was the need to rely
on studies that were largely observational. The potential for
confounding and bias should therefore be considered when
interpreting the results and the observed level of heterogeneity of
the results.
Figure 6. Meta-analysis for case-control studies using the Mantel-Haenszel fixed effects method (M–H) and the DerSimonian and
Laird random effects (D+L) method for response to influenza H1N1. Numbers in brackets refer to legend in Table 3.
doi:10.1371/journal.pone.0056974.g006
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The second most important finding is that the individual
vaccines investigated have been studied predominately only in one
group of SOT recipients, i.e. tetanus, diphtheria and polio in RTX
recipients, hepatitis A exclusively in adult LTX recipients and
mumps, measles and rubella in paediatric LTX recipients. There
is a clear need to investigate all recommended vaccines across all
SOT types. There is increasing concern about high individual and
SOT-dependant variation in the response to immunosuppressive
drugs in both paediatric and adult SOT recipients [83,84].
Most trials in SOT recipients included in this review have
evaluated influenza vaccines. Variability of the response was very
high and ranged from 0–100% in SOT recipients with
corresponding high values of I-squared (all larger than 92%).
Among other reasons (such as studies conducted over more than
30 years) the varying seasonal composition of influenza vaccines
may play a role and makes comparisons between trials difficult.
When comparing response rates of SOT recipients with controls,
several studies showed a clear trend to a less pronounced response
in SOT recipients with overall a 10% to 16% lower response rate
in SOT recipients. The difference in response to control patients
was in renal and lung transplant recipients somewhat less
pronounced than in the other SOT groups. In some studies,
however, the response rate in SOT recipients was even higher
than in controls, which might reflect the play of chance or the fact
that in some of these studies different vaccination schemes were
used in the two groups (i.e. double dose for SOT recipients and
single dose for controls) or highly differing pre-transplant antibody
levels (higher in SOT recipients than in controls). Almost all trials,
however, observed a measurable vaccine response at least in a
subset of SOT recipients after single dose vaccination with a trend
to lower response rates in SOT recipients compared to healthy
controls in most of the trials, which is encouraging and is in
accordance with findings from other authors [85–87]. In contrast
to other vaccinations, influenza vaccination is recommended
annually to protect against the predicted seasonal strains; rapid
decline of antibodies is, therefore, of marginal relevance. Given the
susceptibility, morbidity and mortality associated with influenza
infections in SOT recipients and the positive response found in
most influenza vaccine trials, recommending annual influenza
vaccination is encouraged by our review of published clinical trials.
The benefit for accelerated vaccination schemes or multi dose
vaccination to increase protection cannot be decided on the basis
of available data.
Good evidence and encouraging results were found for
vaccinating SOT recipients against tetanus, diphtheria and polio.
Vaccination with tetanus toxoid in the post-transplant period
elicits a high rate of responders in SOT recipients with
conventional immunosuppression with no significant difference
to healthy controls (p = 0.96 on only two studies) while immuno-
suppression with anti-CD20 monoclonal antibody showed a
Figure 7. Meta-analysis for case-control studies using the Mantel-Haenszel fixed effects method (M–H) and the DerSimonian and
Laird random effects (D+L) method for response to influenza H3N2. Numbers in brackets refer to legend in Table 3.
doi:10.1371/journal.pone.0056974.g007
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decreased response rate compared to conventional immunosup-
pressive medication (p = 0.043 in meta-regression). All studies with
diphtheria vaccination in the post-transplant phase show compa-
rable high response rates (I-squared= 0%). From the data
reviewed serological response to tetanus appears to be longer
lasting than to diphtheria vaccination. Long-term response for
tetanus showed persistence of antibodies without relevant decrease
while the response for diphtheria had a 17% (95% CI: 7%–27%)
decline over time in SOT recipients.
Response to polio vaccination also seems to be elicitable in SOT
recipients, even though only one trial has investigated this vaccine.
However, as polio eradication suffers from backlashes and
international travel of SOT recipients is increasing, polio
vaccination in SOT recipients is important and deserves further
exploration.
Vaccination trials for viral hepatitis A and B have largely been
conducted in LTX recipients and results can only be extrapolated
to other SOT types with great care. Results for HAV vaccination
show a high degree of heterogeneity (I-squared= 97.7%), while
one study shows high response rates for both RTX and LTX,
others did not confirm this finding. Response rate to HBV after
transplantation in adult SOT recipients is poor while in paediatric
SOT recipients a 58% (95 CI: 37%–80%) higher response rate
was seen (p = 0.001 from meta-regression). The results of primary
vaccination after SOT are disappointing as early response rates
were low in almost all trials and long-term responses have not been
assessed on a large scale. In one study, however, long-term
response was assessed and antibodies for HAV were declining
rapidly. The response for hepatitis A had a 41% (95% CI: 26%–
57%) decline over time in SOT recipients.
In the light of this finding, the importance of hepatitis A and B
vaccination prior to transplantation should be markedly stressed in
pre-transplant assessment and counselling. The immunogenicity of
both vaccines needs to be extended beyond LTX and should be
evaluated in recipients of organs other than liver.
Vaccination against bacterial pathogens is of great importance
for immunosuppressed recipients. Response rate in all Streptococcus
pneumoniae studies was above 50% with a summary estimate of 83%
(95% CI: 83%–93%) with substantial heterogeneity (I-
squared= 81%), for Haemophilus influenzae vaccines (Hib) a response
rate above 50% in SOT recipients in both studies was observed as
well as for Neisseria meningitides (100%).
Assessment of the response to pneumococcal vaccines is difficult
due to the large numbers of serotypes included in the vaccines
(conjugate vaccine with 7 serotypes and polysaccharide vaccine
with 23 serotypes) and the unclear impact of the seroresponse
measured on protection. The response rate assessed here might be
overestimated as we accepted the serological response to a single
antigen as positive response. However, even in healthy children
and adults, vaccine-, serotype-, and population-specific differences
Figure 8. Meta-analysis for case-control studies using the Mantel-Haenszel fixed effects method (M–H) and the DerSimonian and
Laird random effects (D+L) method for response to influenza B. Numbers in brackets refer to legend in Table 3.
doi:10.1371/journal.pone.0056974.g008
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in immune response is not readily understood [88,89]. Most
guidelines, nevertheless, recommend pneumococcal vaccines for
SOT recipients. From current data it cannot be assessed if
conjugate pneumococcal vaccines are superior to polysaccharide
vaccines in SOT recipients.
Vaccines for protection of travel-related infections in SOT
recipients have, with very few exceptions, not been studied so far.
Due to increasing quality of life, SOT recipient are willing to travel
and a thorough assessment of their vaccination status is therefore
necessary [90,91]. Also, it is important to note that some of these
infections are highly endemic or epidemic in countries where
SOTs are now also regularly performed. Rabies is an example. We
could identify only a single and very small trial on rabies post-
exposure prophylaxis. The summary response rate estimate seen in
these nine SOT recipients was 89% (95% CI: 52%–100%). These
results are encouraging for rabies vaccination in SOP recipients.
From a global point of view research in this area is warranted.
Vaccination of SOT recipients with live-attenuated viral
vaccines remains controversial and is clinical studies are currently
limited to paediatric SOT recipients [92–94]. Generally, live
vaccines are contraindicated in immunocompromised recipients as
there is a risk of vaccine-virus replication. As all other trials
identified in our review, the trials investigating live vaccines are
also underpowered to assess severe adverse events (SAEs) with
appropriate accuracy. For live-attenuated varicella vaccination
acceptable response rates were observed in all studies with an
overall estimate of 73% (95% CI: 64%–83%) with little
heterogeneity (I-squared = 0%) in SOT recipients after post-
transplantation vaccination are seen. For mumps, measles and
rubella positive response rates were above 70% in all but one study
conducted in 1993, resulting in a summary estimate of 85% (95%
CI: 72%–99%) with substantial heterogeneity (I-squared= 76%).
Omitting the 1993 study reduced heterogeneity substantially (I-
squared= 36%). In terms of vaccination response, the trials
presented here show encouraging results at least for paediatric
recipients. The trials so far performed were very small, however,
and do not allow to assess the risk-benefit ratio of vaccination vs.
infections for e.g. measles or varicella. The underpowerment is a
problem to accurately assess vaccine-related SAEs in SOT
recipients in all trials conducted so far. On theoretical grounds
the risk of SAE is expected to be less in inactivated compared to
live-attenuated vaccines. On the basis of currently available
evidence application of live vaccines should remain limited to
carefully monitored trials until more data on safety are available.
Instead, indirect protection of SOT recipients by vaccination of
household contacts is stressed by all authors.
Vaccination aims for long-term protection after initial immu-
nization. To which extent this can be achieved in SOT recipients
is unclear. Only few studies assessed a long-term response after
$12 months. Long-term response for tetanus showed persistence
of antibodies without relevant decrease while response for
diphtheria had a 17% (95% CI: 7%–27%) and the one for
Figure 9. Forest plot for studies investigating both short-term response (grey bars and numbers) and long-term response (black
bars and numbers).
doi:10.1371/journal.pone.0056974.g009
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hepatitis A 41% (95% CI: 26%–57%) decline over time in SOT
recipients. Based on this limited number of studies that assessed
both short- and long-term response to vaccinations no recom-
mendation on adaptation of general recommendations for booster
intervals for SOT recipients can be given.
Limitations of our review are that, despite the use of systematic
search strategies, some trials may have been missed, particularly
since the search was limited to trials published in English. We did
not assess the quality of the trials. All trials included in this review
were, however, published in peer-reviewed journals. Only
publications in which essential key data were missing were
excluded. Since we did not restrict our search to a specific
publication period, older trials using out-dated immunosuppressive
regimens, which are no longer relevant, may have been included.
We are aware that the type of immunosuppressive treatment
impacts on the vaccine response. Stratification by type of
immunosuppressive treatment would have, however, further
fragmented the presentation of available data with the result of
even smaller numbers per stratum. Equally, we did not exclude
trials on the basis of the time period between SOT and vaccination
despite the fact that the first 6 months after transplantation is
regarded as the period during which immunosuppression is
highest.
Additional potential sources of heterogeneity in positive
response to vaccination were substantial loss to follow-up and
often unknown and possibly varying levels of pre-transplant
immunity to the infections covered in the respective vaccines. An
unknown vaccination status of a SOT recipient represents,
however, a situation frequently seen in clinical practice and
requires a pragmatic approach.
With these caveats in mind, we believe that this review
comprehensively presents the current knowledge on vaccination
response in SOT recipients.
Interpretation
Vaccine-based prevention of infectious diseases is far from
satisfactorily in solid organ transplant recipients. Despite the large
number of vaccination trials preformed over the past decades,
knowledge on vaccination response after SOT is still limited. Even
though the protection, which can be achieved in SOT recipients
through vaccination, appears encouraging on the basis of available
data, current vaccination guidelines and recommendations for
post-SOT recipients remain poorly supported by evidence. There
is an urgent need to conduct appropriately powered vaccination
trials with relevant endpoints in well-defined SOT recipient
cohorts, as well as to increase the awareness of clinicians for timely
pre-transplant vaccination.
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